A combined triple therapy comprising fluticasone furoate (an ICS*), umeclidinium (a LAMA**), and vilanterol (a LABA***) in a single inhaler significantly lowers the rate of moderate or severe exacerbations compared with dual therapies of either ICS-LABA or LAMA-LABA in patients with symptomatic chronic obstructive pulmonary disease (COPD) and a history of exacerbations, the IMPACT# study shows.
Aclidinium bromide does not increase the risk of major adverse cardiac event (MACE) in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) who also had significant cardiovascular (CV) risk factors, according to the phase IV ASCENT COPD* study presented at ATS 2018.
Long-term use of inhaled corticosteroids (ICSs) at daily doses of ≥1,000 µg was associated with a modest but significant increase in nonvertebral fracture risk in patients with chronic obstructive pulmonary disease (COPD), according to a real-world study.
Aspirin use in patients with acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) is associated with lower rates of in-hospital mortality, reduced use of invasive mechanical ventilation and shorter hospital length-of-stay, a study suggests.
Intermittent high-dose glucocorticoids (GCs) therapy does not contribute to an increase in the risk of any, osteoporotic, hip or clinically symptomatic vertebral fractures in patients with chronic obstructive pulmonary disorder (COPD), according to a study. However, current GC use appears to increase the risk of hip and clinically symptomatic vertebral fractures.
Treatment with beta-blockers does not appear to influence lung function, overall respiratory status and safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disorder (COPD), according to data from the TONADO research programme.
There appears to be a high rate of emergency department (ED) admission for acute exacerbation of chronic obstructive pulmonary disease (AECOPD), with patients having significant in-hospital mortality, according to data from the *AANZDEM study. Furthermore, compliance with evidence-based treatments in the ED is suboptimal.
New drug applications approved by US FDA as of 1 - 15 December 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Use of inhaled corticosteroid (ICS), particularly fluticasone, was associated with an increased risk of nontuberculous mycobacterial (NTM) lung infections in older people with obstructive lung disease, according to a population-based study in Canada.
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.